Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1989 1
1990 1
1992 1
1997 2
1998 3
1999 1
2000 1
2001 3
2002 4
2003 1
2004 6
2005 3
2006 5
2007 6
2008 7
2009 5
2010 3
2011 3
2012 3
2013 6
2014 5
2015 2
2016 10
2017 10
2018 9
2019 9
2020 17
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

126 results
Results by year
Filters applied: . Clear all
Page 1
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. Kim H, et al. Among authors: jahnsen j. Drugs. 2020 Feb;80(2):99-113. doi: 10.1007/s40265-020-01256-5. Drugs. 2020. PMID: 32002851 Free PMC article. Review.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK. Goll GL, et al. Among authors: jahnsen j. J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12. J Intern Med. 2019. PMID: 30762274 Free PMC article. Clinical Trial.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Among authors: jahnsen j. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Self-esteem in patients with inflammatory bowel disease.
Opheim R, Moum B, Grimstad BT, Jahnsen J, Prytz Berset I, Hovde Ø, Huppertz-Hauss G, Bernklev T, Jelsness-Jørgensen LP. Opheim R, et al. Among authors: jahnsen j. Qual Life Res. 2020 Jul;29(7):1839-1846. doi: 10.1007/s11136-020-02467-9. Epub 2020 Mar 6. Qual Life Res. 2020. PMID: 32144613 Free PMC article.
[Correction: A man in his fifties with abdominal pain, itching and weight loss].
Bjørlykke KH, Eftang LL, Grzyb K, Line PD, Lassen K, Jahnsen J. Bjørlykke KH, et al. Among authors: jahnsen j. Tidsskr Nor Laegeforen. 2020 Mar 13;140(4). doi: 10.4045/tidsskr.20.0137. Print 2020 Mar 17. Tidsskr Nor Laegeforen. 2020. PMID: 32192268 Free article. Norwegian. No abstract available.
[Measurement of calprotectin in faeces].
Jahnsen J, Røseth AG, Aadland E. Jahnsen J, et al. Tidsskr Nor Laegeforen. 2009 Apr 16;129(8):743-5. doi: 10.4045/tidsskr.08.0010. Tidsskr Nor Laegeforen. 2009. PMID: 19373299 Free article. Review. Norwegian.
126 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page